This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.
Age ≥ 18 years old
Patients must have histologic confirmation of follicular lymphoma (FL) (grade 1, 2, and 3A or classic follicular lymphoma)
Involvement of ≥ 3 nodal sites, each with diameter of ≥ 3 cm.
Any nodal or extranodal tumor mass with a diameter of ≥ 7 cm.
FL grade 3B or transformed FL
Patients receiving any other investigational agents
Patients with known central nervous system involvement of lymphoma
History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the primary investigator (PI) may be included
University of Washington
Lead sponsor
Incyte Corporation
Collaborator